Harmony Biosciences (HRMY) Tops Q2 EPS by 9c

Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $0.57, $0.09 better than the analyst estimate of $0.48. Revenue for the quarter came in at $107 million versus the consensus estimate of $100.73 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c
• Exyn Technologies, Inc. (EXYN) Reports Q2 Loss of $1.55